Should BioMarin’s Cost Cuts, Roctavian Exit, and Pipeline Shifts Require Action From BMRN Investors?

Simply Wall St.12-14

Earlier this month, BioMarin Pharmaceutical’s CEO reported that the company’s US$500 million cost transformation program is about two-thirds complete and reiterated an ambition to reach a 40% non-GAAP...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591462659?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-14 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591462659","market":"hk","top_or_hot":-1,"title":"Should BioMarin’s Cost Cuts, Roctavian Exit, and Pipeline Shifts Require Action From BMRN Investors?","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, BioMarin Pharmaceutical’s CEO reported that the company’s US$500 million cost transformation program is about two-thirds complete and reiterated an ambition to reach a 40% non-GAAP...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/should-biomarins-cost-cuts-roctavian-exit-and-pipeline-shift\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should BioMarin’s Cost Cuts, Roctavian Exit, and Pipeline Shifts Require Action From BMRN Investors?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould BioMarin’s Cost Cuts, Roctavian Exit, and Pipeline Shifts Require Action From BMRN Investors?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-14 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/should-biomarins-cost-cuts-roctavian-exit-and-pipeline-shift><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this month, BioMarin Pharmaceutical’s CEO reported that the company’s US$500 million cost transformation program is about two-thirds complete and reiterated an ambition to reach a 40% non-GAAP...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/should-biomarins-cost-cuts-roctavian-exit-and-pipeline-shift\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4566","symbol_name":"资本集团","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/should-biomarins-cost-cuts-roctavian-exit-and-pipeline-shift","article_id":"2591462659","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/should-biomarins-cost-cuts-roctavian-exit-and-pipeline-shift","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591462659","pubTimestamp":1765671621,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, BioMarin Pharmaceutical’s CEO reported that the company’s US$500 million cost transformation program is about two-thirds complete and reiterated an ambition to reach a 40% non-GAAP operating margin next year, while also reshaping the portfolio through workforce reductions and discontinuation of the Roctavian program.\nAt the same time, analysts have raised concerns about rising competition in achondroplasia and potential gaps in BioMarin’s pipeline, even as they...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4566":"资本集团","BMRN":"拜玛林制药","BK4211":"区域性银行","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","ISBC":"投资者银行","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4139":"生物科技","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"BioMarin的成本削减、Roctavian退出和管道转移是否需要BMRN投资者采取行动？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"BMRN":1.5},"content_text":"Earlier this month, BioMarin Pharmaceutical’s CEO reported that the company’s US$500 million cost transformation program is about two-thirds complete and reiterated an ambition to reach a 40% non-GAAP operating margin next year, while also reshaping the portfolio through workforce reductions and discontinuation of the Roctavian program. At the same time, analysts have raised concerns about rising competition in achondroplasia and potential gaps in BioMarin’s pipeline, even as they acknowledge that moves like the Inozyme acquisition could help rebuild longer-term growth options. We’ll now examine how BioMarin’s cost transformation and pipeline concerns might reshape the existing investment narrative for the company. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.BioMarin Pharmaceutical Investment Narrative RecapTo own BioMarin today, you need to believe that its rare disease franchise, led by VOXZOGO, can keep growing while the company delivers on its US$500 million cost transformation and margin ambitions. The latest update on operating targets and the Roctavian exit does not materially change the near term focus on VOXZOGO execution as the key catalyst, but it does sharpen competition and pipeline depth as the main risks to watch. In that context, Leerink’s downgrade and comments about rising achondroplasia competition and a potential pipeline gap feel particularly relevant, because they directly question the durability of VOXZOGO and follow on programs as growth pillars. The same report acknowledges that measures like the Inozyme acquisition could eventually broaden the portfolio, but investors may want to see clearer evidence that these moves can offset competitive pressure around VOXZOGO and BMN 333. Yet even with cost cuts progressing, investors should be aware that intensifying competition around achondroplasia could... Read the full narrative on BioMarin Pharmaceutical (it's free!)BioMarin Pharmaceutical's narrative projects $3.8 billion revenue and $1.1 billion earnings by 2028.Uncover how BioMarin Pharmaceutical's forecasts yield a $89.36 fair value, a 68% upside to its current price.Exploring Other PerspectivesBMRN 1-Year Stock Price Chart Four members of the Simply Wall St Community currently estimate BioMarin’s fair value between US$83.91 and US$142.52, highlighting a very wide spread of expectations. You can weigh these views alongside the risk that stronger competition in rare skeletal disorders could pressure VOXZOGO and BMN 333 and consider what that might mean for BioMarin’s future earnings power.Explore 4 other fair value estimates on BioMarin Pharmaceutical - why the stock might be worth just $83.91!Build Your Own BioMarin Pharmaceutical NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your BioMarin Pharmaceutical research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free BioMarin Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioMarin Pharmaceutical's overall financial health at a glance.Ready To Venture Into Other Investment Styles?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.Find companies with promising cash flow potential yet trading below their fair value.Uncover the next big thing with financially sound penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechValuation is complex, but we're here to simplify it.Discover if BioMarin Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591462659","isCrawlerRequest":true}